Şunu aradınız:: multicenter (İngilizce - Maltaca)

single center multicenter study
single center

study 138 is an international randomised, open-label, multicenter, prospective trial of
studju 138 huwa prova prospettiva, multiċentri, open-label, randomizzata, internazzjonali ta’

the efficacy of infliximab was assessed in two multicenter, randomised, double blind studies:
psorajiżi l- effikaċja ta ’ infliximab kienet evalwata f’ żewġ studji multiċentriċi, randomised, double- blind:

most of the primary immunogenicity studies were conducted as randomized, controlled, multicenter, clinical trials.
il-biċċa l-kbira tal-istudji dwar immunoġeniċità primarja twettqu bħala provi kliniċi li fihom il-parteċipanti ntgħażlu b'mod każwali, ikkontrollati u multiċentriċi.

study 2 was a randomized, controlled, multicenter study comparing the zevalin therapeutic regimen versus treatment with rituximab.
studju 2 kien studju randomised, ikkontrollat, b’aktar minn ċentru wieħed li qabbel il-kors terapewtiku ta’ zevalin ma’ kura b’rituximab.

the immunogenicity of prevenar has been investigated in an open-label, multicenter study in 49 infants with sickle cell disease.
l-immunoġeniċità ta’ prevenar kienet investigata fi studju open-label, multiċentriku f’49 tarbija bil- marda taċ-ċelluli sickle.

paediatric patients the safety and efficacy of cancidas was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials.
pazjenti pedjatriċi is- sigurtà u l- effikaċja ta ’ cancidas ġiet evalwata f’ pazjenti pedjatriċi minn 3 xhur sa 17- il sena f’ żewġ provi kliniċi prospettivi multiċentri.

the efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: spirit and express.
l-effikaċja ta’ infliximab kienet evalwata f’żewġ studji multiċentriċi, li fihom il-parteċipanti ntgħażlu b’mod każwali, double-blind: spirit u express.

efficacy in pediatric studies ertapenem was evaluated primarily for pediatric safety and secondarily for efficacy in randomized comparative, multicenter studies in patients 3 months to 17 years of age.
10 effikaċja fi studji pedjatriċi ertapenem kien evalwat l- ewwel għas- sigurtà pedjatrika u t- tieni għall- effikaċja fi studji randomized, komparattivi u multiċentriċi f' pazjenti ta 'bejn it- 3 xhur u s- 17- il sena.

data from a multicenter open label randomized trial support the use of docetaxel kabi for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy.
tagħrif minn studju li sar f’ċentri multipli, fejn kemm il-pazjenti kif ukoll l-investigaturi kienu jafu x’mediċini qed jintużaw u fejn il-pazjenti tqassmu b’mod arbitrarju, isaħħah l-użu ta’ docetaxel kabi għat-trattament miżjud f’pazjenti li għandhom kanċer operabbli tas-sider li ma nfirixx fil- glandoli limfatiċi u li huma eliġibbli biex jirċievu l-kimoterapija.

voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic hsct recipients without prior proven or probable ifi.
voriconazole ġie mqabbel ma’ itraconazole bħala profilassi primarja fi studju bit-tikketta tingħaraf, komparattiv, multiċentriku, ta’ riċevituri alloġeniċi adulti u adolexxenti ta’ hsct mingħajr ifis li ġew ikkonfermati jew li setgħu seħħew fil-passat.

assessment of the pharmacokinetics, safety, tolerability, and virologic response of reyataz oral powder was based on data from two open-label, multicenter clinical trials.
il-valutazzjoni tal-farmakokinetika, is-sigurtà, it-tollerabbiltà, u r-rispons viroloġiku ta’ reyataz trab orali kienet ibbażata fuq id-dejta minn żewġ provi kliniċi multiċentriċi, b’tikketta mikxufa.

1- an open-label, randomised, non-comparative multicenter study was conducted in patients who failed initial treatment with 400 or 600 mg imatinib.
1 - sar studju mhux komparattiv, open- label, fejn l- pazjenti ntgħażlu b’ mod każwali b' aktar minn ċentru wieħed fuq pazjenti li fuqhom, it- trattament tal- bidu b' 400 jew 600 mg ta 'imatinib ma ħadimx.

in two multicenter, randomized, double-blind, placebo-controlled pivotal studies 234 subjects with a recent history of frequent heartburn were treated with 20 mg esomeprazole for 4 weeks.
f’żewġ studji pivitali, multiċentri, randomizzati, double-blind u kkontrollati bil-plaċebo, 234 individwu bi storja riċenti ta’ ħruq ta’ stonku frekwenti kienu kkurati b’20 mg esomeprazole għal 4 ġimgħat.

leflunomide was studied in a single multicenter, randomized, double-blind, active-controlled trial in 94 patients (47 per arm) with polyarticular course juvenile rheumatoid arthritis.
leflunomide kien studjat f’diversi ċentri fi prova waħda, tat-tip randomised, double blind u active- controlled, f’94 pazjent (47 f’kull grupp) li kellhom l-artrite rewmatika taż-żgħażagħ u li nvolviet diversi ġogi tul il-kors tagħha.